Caverject

Quick links to important sections

Caverject

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caverject

Quick Facts

Property Description
Active ingredient Alprostadil (Prostaglandin E1 analogue)
Form Lyophilized powder for injection (sterile powder)
Pharmacological class Vasoactive agent, Vasodilator
Common use Facilitates tissue rigidity and expansion
Origin Synthetic

The Identity of Caverject and Its Pharmacological Classification

Caverject is a prescription-only medicine whose active component is Alprostadil, which is classified as both a vasoactive agent and a Prostaglandin analogue. This substance is the synthetic, chemically-identical version of Prostaglandin E1 (PGE1), a naturally occurring lipid compound. Alprostadil belongs to a class of medications called vasodilators that function by relaxing muscles and blood vessels. This principle is clinically recognized to be highly effective due to the substance's ability to mimic and intensify a precise, existing biochemical signal.

Composition and Pharmaceutical Form

The medicine is supplied as a lyophilized powder for injection, which is a sterile, freeze-dried substance requiring reconstitution with sterile water before it can be used. This specific dosage form is intrinsically linked to its intended local route of administration (penile injection). The preparation contains additional inactive ingredients such as lactose and sodium citrate. Unlike oral medications that are distributed systemically, this localized powder form guarantees direct, efficient delivery of the vasoactive agent to the targeted tissues.

The General Purpose of This Vasoactive Agent

The fundamental purpose of Caverject is to rapidly initiate physiological changes by causing significant relaxation of smooth muscle within the targeted vascular structures. By utilizing the potent vasodilating properties of the Alprostadil analogue, the product triggers a powerful hemodynamic effect that alters the local balance of blood flow. This agent acts by relaxing the smooth muscles of the corpus cavernosum and by increasing the diameter of cavernous arteries. Therefore, its primary general benefit is to facilitate the necessary changes in blood flow and pressure within the area required to support tissue firmness and expansion.

Regulatory References

  1. NIH MedlinePlus Drug Information for Alprostadil
  2. MedlinePlus Drug Information for Alprostadil

What side effects are possible with Caverject?

Possible Side Effects and Safety Information

The safety profile of Caverject (Alprostadil) is classified in official regulatory documents based on the frequency and the body system affected. Since this medicine is administered locally, the majority of documented reactions involve the reproductive system and the injection site. All listed reactions are strictly defined by regulatory authorities like the FDA and EMA.


Adverse Reaction Frequency

Classification Example Reaction Context
Most Common (ge 10%) Penile pain The most frequently reported adverse reaction in clinical studies.
Common (ge 1% to < 10%) Prolonged erection (4–6 hours), Penile fibrosis, Dizziness Also includes injection site reactions such as hematoma and ecchymosis.

Clinically Significant Adverse Reactions

The regulatory profile highlights the risk of specific, clinically important adverse events, which are generally categorized under Serious Adverse Reactions.

  • Priapism: This is defined as a prolonged erection lasting six hours or longer. This serious reaction warrants careful safety attention.
  • Penile Fibrosis: The development of cavernosal fibrosis, penile angulation, or signs of Peyronie's disease is documented, with the risk noted to potentially increase with increased duration of use.

Safety Constraints and Special Populations

Official labeling defines specific safety constraints for patient selection. The medicine is generally contraindicated in individuals with certain underlying conditions, particularly those that may predispose them to priapism, such as sickle cell anemia or trait, or pre-existing conditions like anatomical deformation of the penis (e.g., severe angulation). Furthermore, concomitant use with other intracavernosally injected vasoactive agents is not established, and there is an increased propensity for bleeding at the injection site in patients receiving anticoagulant therapy.

Overdose and Emergency Response

The official regulatory documents define the manifestations and required emergency actions for an overdose of Caverject. The primary local manifestation of an overdose is a prolonged erection, which is typically described as one lasting for four to six hours. Overdose may also be associated with systemic symptoms, including hypotension (low blood pressure), dizziness, fainting, blurred vision, and nausea.

An erection persisting for more than four hours is considered a medical emergency and officially requires the patient to seek immediate medical assistance. An erection lasting over six hours is classified as priapism. If priapism is not treated promptly, it can lead to severe and irreversible outcomes, including penile tissue damage and permanent loss of potency, according to regulatory labeling.

No specific antidote is documented for Caverject overdose; therefore, management is described as symptomatic and supportive. Following a potential overdose or occurrence of a prolonged erection, regulatory guidance requires the patient to remain under medical supervision. This monitoring must continue until any systemic effects have fully resolved and until penile detumescence, meaning the return to a non-erect state, has successfully occurred. No specific population-related overdose risks for this formulation are noted in the official prescribing information for adult males.

Therapeutic Uses of Caverject

What Caverject Treats: Main Uses and Benefits

Caverject is generally applied in addressing conditions associated with acute or disruptive episodes of erectile dysfunction (ED) in adult males. This medication is commonly used to help with symptomatic relief in adult males experiencing symptoms that interfere with daily functioning.

This therapeutic domain helps address the core symptomatic cluster of insufficient tissue rigidity and the functional inability to maintain an erection. Its primary therapeutic benefit helps offer supportive relief when short-term symptomatic assistance is needed, contributing to easing the overall symptom load. The medication is applied in managing symptoms stemming from underlying physical conditions, such as vasculogenic or neurogenic etiologies, and is also considered relevant in contexts involving heightened systemic burden for supporting clinical evaluation.


Quick Fact: Relief for Functional Impairment
Primary Focus Symptoms of insufficient penile tissue rigidity
Common Contexts Erectile dysfunction (ED)
Type of Relief Supportive relief for functional stability
Relevant Scenarios Applied in scenarios where additional management of discomfort is required

Eligibility and Restrictions for Use

Who Can and Cannot Use Caverject? (Official Eligibility Profile)

The official regulatory profile for Caverject strictly defines patient eligibility based on age, specific health conditions, and anatomical integrity. The medicine is indicated solely for use in adult males (18 years and older).

Contraindicated Populations

Use is contraindicated and explicitly prohibited in several populations, as stated in regulatory labeling:

  • Males with conditions that predispose to priapism (a prolonged erection), such as sickle cell anemia or trait, multiple myeloma, or leukemia.
  • Males who have an anatomical deformation of the penis, including severe angulation, cavernosal fibrosis, or Peyronie’s disease.
  • Males with a penile implant.
  • Patients with a known hypersensitivity to the active ingredient, Alprostadil, or any excipients.

Age- and Condition-Based Restrictions

Caverject is not indicated for use in children or adolescents under 18 years of age. Furthermore, use is not recommended for men whose underlying cardiovascular status makes sexual activity medically inadvisable. No unique eligibility restrictions are specified for older adults. The safety and efficacy of combining Caverject with other intracavernosally injected vasoactive agents are not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Caverject (Alprostadil) is predominantly defined by pharmacodynamic (PD) interactions due to its localized administration, rather than systemic metabolic interactions.

Vasoactive Agents and Related Restrictions

Official regulatory documents restrict the concurrent use of Caverject with certain medicinal products. Other vasoactive agents administered by intracavernosal injection are not recommended for co-administration. This restriction is based on the potential for an additive pharmacodynamic effect that may result in an increased risk of prolonged erection. The safety and efficacy of such combinations have not been systematically studied by regulatory bodies.

Substances Affecting Bleeding

Patients who are concurrently receiving anticoagulants, such as warfarin or heparin, may experience an increased propensity for bleeding at the injection site. This is a local PD effect documented in official prescribing information.

Pharmacokinetic and Exposure Modification

The potential for systemic pharmacokinetic (PK) drug-drug interactions between Caverject and orally administered agents has not been formally studied in regulatory clinical trials. Consequently, there are no documented interactions that formally alter the systemic clearance, AUC, or plasma concentrations of Caverject. No specific interactions with food, alcohol, or herbal products are documented in the official prescribing information.

Mechanism of Action

Prostaglandin Receptor Activation and Smooth Muscle Control

The mechanism is initiated by the molecule acting as a direct agonist on specific Prostaglandin E receptors ( EP2 and EP4) located on smooth muscle cells within the penile tissue. This receptor activation triggers the enzyme Adenylate Cyclase, which subsequently increases the intracellular concentration of the second messenger cyclic AMP ( cAMP). The resulting cAMP signaling reduces the internal calcium ion concentration required for muscle contraction. This action modulates the tissue’s basal smooth muscle tone, leading directly to the relaxation of both arterial and trabecular smooth muscle.

Hemodynamics and Veno-Occlusion Cascade

The relaxation of the smooth muscle causes local vasodilation (widening of the arteries), allowing for increased blood flow into the penile tissues. The resulting change in local hemodynamics physically expands the blood-holding spaces, which mechanically compresses the venules responsible for local drainage. This veno-occlusion cascade traps the blood locally, contributing to the increase in internal pressure and tissue rigidity.

Dosage and Administration Information

Administration Guidelines: Intracavernosal Injection

Route of Administration and Preparation

Caverject (alprostadil) is administered by intracavernosal injection, meaning it is injected directly into the corpora cavernosa of the penis. The lyophilized powder must be reconstituted with the provided diluent immediately prior to use. The reconstituted solution must be visually inspected and discarded if discoloration or particulate matter is present. The injection system is for single use only and must not be reused or shared.


Dosing and Frequency Rules

The dosage is strictly individualized through careful titration in a physician's office to find the lowest effective dose. The objective is to achieve an erection suitable for intercourse that does not exceed a duration of one hour. Doses greater than 60 micrograms (mug) are generally not recommended.

  • Initial Titration (Vasculogenic/Psychogenic/Mixed Etiology): Begin with a 2.5 mug dose.
  • Initial Titration (Pure Neurogenic Etiology): Begin with a 1.25 mug dose.

Following the establishment of the optimal dose, the recommended frequency is no more than three times weekly, with an interval of at least 24 hours between each injection.


Procedural Requirements

The first injections must be administered by medically trained personnel in a healthcare setting. Patients must be thoroughly instructed and trained in the self-injection technique before starting home use. The injection site must be along the dorsolateral aspect of the proximal third of the penis, avoiding visible veins, and the injection side and specific site must be alternated with each subsequent use.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Caverject (alprostadil) is a synthetic form of Prostaglandin E1 (PGE1) studied as a second-line treatment for erectile dysfunction (ED). Research has evaluated its use across various etiologies of ED, including psychogenic, vasculogenic, and neurogenic causes.


Core Efficacy Findings

Multiple randomized, double-blind, placebo-controlled clinical trials have been conducted to determine the drug's effectiveness. These studies typically established an individualized optimal dose for each participant during an in-office titration phase before proceeding to at-home use.

  • Response Rates: In core clinical studies, over 80% of patients reported achieving an erection sufficient for sexual intercourse after receiving an intracavernosal injection.
  • Duration: The mean reported duration of erection after injection in long-term, at-home studies was often around 67 to 70 minutes.
  • Satisfaction: In one 6-month open-label study involving men with ED of various origins, approximately 87% of all injections administered resulted in satisfactory sexual activity.

Safety and Long-Term Observations

Clinical trials have closely monitored the drug's safety profile over periods of up to 18 months. Although typically effective, the invasive nature of the administration has been associated with patient drop-out rates in some long-term studies.

Observed Adverse Events in Trials

Event Incidence Rate Notes
Penile Pain Most common (around 37%) Generally transient, localized to the injection site.
Prolonged Erection Approximately 4% Defined as lasting 4 to 6 hours.
Penile Fibrosis Approximately 3–8% Requires periodic physical examination to detect.

Serious adverse events like priapism (erections lasting over 6 hours) were reported in a small number of patients (around 0.4%). The incidence of these events is minimized through careful dose titration under the guidance of a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Caverject (FAQ)

Q: Is it normal to feel a mild sensation or discomfort after using it?

A: Regulatory sources indicate that the most frequently reported reaction is pain in the penis. This sensation was generally assessed as mild or moderate in nature by patients in clinical studies. This finding is documented in the official product information.

Q: Is Caverject the same drug as the Alprostadil cream or tablets?

A: Caverject contains Alprostadil, which is the same active substance found in other treatments for erectile dysfunction. However, Caverject is strictly an intracavernosal injection, meaning it is administered directly into the tissue. This distinction in the route of administration sets it apart from topical cream or urethral suppository forms of Alprostadil.

Q: What are the concerns about using Caverject long-term?

A: Official prescribing information notes the development of penile fibrosis, which includes penile angulation or Peyronie's disease, as a documented concern. This risk may increase with the duration of the drug’s use. Regulatory warnings mention that periodic physical examination is necessary to detect potential fibrosis.

Q: Are there any specific lab tests needed before starting Caverject?

A: Official guidance states that underlying treatable medical causes of erectile dysfunction (ED) should be diagnosed and managed before starting therapy. This step is described as helping to identify conditions that may predispose a person to a prolonged erection.

Q: What does the evidence say about the expected success rate of Caverject?

A: Studies and official information indicate a high rate of response in patients. For instance, core clinical trials reported that a high percentage of injections resulted in satisfactory sexual activity, often around 88% in one study over six months.

Q: How do research trials describe the 'satisfaction' when using Caverject?

A: In clinical trials, patient satisfaction was documented based on whether the injection resulted in successful sexual activity. This successful activity was defined to include both sexual intercourse and masturbation.

Q: Is there any information on Caverject use for patients after prostatectomy?

A: Official documents indicate the drug is approved for treating erectile dysfunction caused by neurogenic factors. Since ED following a prostatectomy procedure is often categorized as a neurogenic cause, the medicine is indicated for this type of use.

Q: Is Caverject a permanent solution for erectile dysfunction?

A: The drug is intended as an acute, on-demand treatment for erectile dysfunction. According to the official dosing and frequency rules, it is for use on an as-needed basis. Official documents do not describe the medicine as a permanent solution or cure for the underlying condition.

Q: Can Caverject be used by people who have heart conditions?

A: Official prescribing information contraindicates the use of the drug in individuals with specific conditions, such as severe heart disease, for whom sexual activity is not recommended by a healthcare professional. The contraindication is specific to individuals with conditions for whom sexual activity is not recommended.

Q: Are there any specific activities or foods to avoid when using Caverject?

A: Official documents do not list specific foods or activities that must be strictly avoided as a part of using the medicine. However, official warnings note that individuals with heart or lung issues are generally cautioned about engaging in sexual activity.

Q: Do older men use Caverject differently than younger men?

A: Official dosing guidelines for the drug are based on the individual's response and the underlying cause of the erectile dysfunction (the etiology). The guidelines do not specify different dosing or administration instructions solely based on the patient's age.

Q: Can Caverject be used if a person has penile implants or has had surgery?

A: Official documentation strictly states that the medicine should not be used in patients who have a penile implant. This is listed as a contraindication.

Q: Is there a maximum number of times Caverject can be used in a month?

A: Official regulatory documentation specifies a maximum use frequency of no more than three times weekly. Additionally, there must be an interval of at least 24 hours between each injection. A monthly maximum is not explicitly defined in the official prescribing information.

Q: Can Caverject affect fertility or sperm count?

A: Official information states that the medicine can be used by couples who wish to conceive. This regulatory statement implies that the drug is not documented to have an effect on fertility that would prevent conception.

Q: Can Caverject be used while drinking alcohol?

A: Official regulatory information does not list any specific or documented interactions between the drug and alcohol consumption.

Q: What is the difference between Caverject and other injectable ED treatments?

A: Regulatory information restricts the concurrent use of the medicine with other vasoactive agents administered by intracavernosal injection. The safety and efficacy of combining such treatments have not been systematically studied by regulatory bodies, and such combinations are generally not recommended.

Q: What happens if Caverject is used too often?

A: Exceeding the recommended frequency of use increases the potential risk for certain adverse events. These risks include the possibility of a prolonged erection (lasting 4–6 hours) and the development of penile fibrosis.

Q: Does Caverject work for all causes of erectile dysfunction?

A: The drug is indicated for the treatment of erectile dysfunction in adult males due to several different causes, including neurogenic, vasculogenic, psychogenic, or mixed etiologies.

Q: Can Caverject be used by men with diabetes?

A: Official product information supports the use of the drug for men with erectile dysfunction related to complications from diabetes. Official warnings note that caution and close monitoring are typically needed due to potential underlying cardiovascular risk factors associated with diabetes.

Q: Are there different strengths or formulations of Caverject?

A: The medicine is available in various strengths for injection (e.g., 5, 10, 20, or 40 micrograms). It is also offered in different delivery system formulations, such as the standard Caverject and the Caverject Impulse systems.

Q: What steps should be taken if a reaction seems different than expected?

A: If an erection lasts for a prolonged period, such as four hours or longer, regulatory guidance states that immediate medical attention is necessary. This action addresses the risk of priapism, a potentially serious adverse reaction.

Q: Is it mandatory to wait a certain period between uses of Caverject?

A: Regulatory documentation states that the recommended interval between each injection is at least 24 hours. The drug should also not be used more than three times within a single week.

Q: Does using Caverject cause dependence on the medicine?

A: While official documents do not explicitly mention physical dependence, regulatory warnings note that the potential for abuse of the drug should be considered. This caution applies to patients who may have a history of psychiatric disorder or addiction.

Q: Are there known interactions between Caverject and herbal supplements?

A: Patients are generally advised to inform their healthcare provider about all medicines they take, including vitamins and herbal supplements.

Q: Is Caverject approved for all ages of adult men?

A: The drug is indicated and approved for use in adult males who experience erectile dysfunction. Official documentation strictly notes that it is not indicated for use in children or newborns.

Q: Is Caverject known to cause any reactions that affect the skin generally?

A: In addition to reactions at the injection site, the regulatory profile documents the potential for general reactions like itching, skin rash, or hives, which can be symptoms of a severe allergic reaction. Other local skin-related reactions like penile rash or discoloration are also documented.

Q: What if the effect of Caverject is less than expected?

A: If the effect is less than expected (a partial response), official guidance notes that the dose may require adjustment. This dose adjustment should only be determined after consulting with the prescribing healthcare provider.

Q: What happens if Caverject is accidentally mixed with another medicine?

A: Regulatory instructions strictly require that only the provided diluent should be used to reconstitute the powder. The drug should not be mixed with any other liquid, as this could affect the solution’s stability or safety profile.

Q: What is the general idea of how Caverject impacts blood flow?

A: The medicine works by relaxing the smooth muscles within the penile tissues and widening the local blood vessels. This allows for increased blood flow into the penis, which is the mechanism that results in tissue rigidity.

Q: Are there non-erectile side effects associated with Caverject, like headache?

A: The regulatory profile documents non-erectile reactions such as dizziness, feeling lightheaded, and nausea. These effects can be symptoms of low blood pressure or a heart problem that may occur during sexual activity.

Q: What are the eligibility restrictions related to non-physical health conditions?

A: Regulatory documentation notes that the potential for abuse of the drug should be considered. This factor applies to patients who have a history of psychiatric disorder or addiction, as defined in the official warnings and precautions.

Q: Does the time of day matter when using Caverject?

A: Official regulatory documentation does not specify that the time of day for injection is a factor in its use. The key administration constraints are ensuring that the recommended minimum 24-hour interval between doses is respected.

Q: Does Caverject interact with common pain relievers like ibuprofen?

A: Patients are generally advised to inform their healthcare provider about all medicines, including over-the-counter pain relievers, as part of the general safety steps.

How should Caverject be stored and disposed of?

How to Store and Dispose of Caverject

Official regulatory documents define strict storage and disposal requirements for Caverject, which contains alprostadil.

Storage Requirements

The unreconstituted powder must be stored in its original container at Controlled Room Temperature, between 20 C to 25 C. The powder must not be allowed to freeze. Once the solution is prepared, it is for single use only and must be used within 24 hours when stored at or below 25 C. The reconstituted solution must not be refrigerated or frozen. All Caverject supplies must be kept out of the sight and reach of children.

Disposal Instructions

All used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container. Needles and syringes must not be discarded into household trash. Used sharps containers should be disposed of according to local community guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caverject found in:

A-Z Index: